Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Depreciation & Amortization (CF) (2018 - 2025)

TransMedics has reported Depreciation & Amortization (CF) over the past 8 years, most recently at $7.5 million for Q4 2025.

  • Quarterly results put Depreciation & Amortization (CF) at $7.5 million for Q4 2025, up 31.48% from a year ago — trailing twelve months through Dec 2025 was $27.1 million (up 38.42% YoY), and the annual figure for FY2025 was $27.2 million, up 37.59%.
  • Depreciation & Amortization (CF) for Q4 2025 was $7.5 million at TransMedics, up from $6.8 million in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for TMDX hit a ceiling of $7.5 million in Q4 2025 and a floor of $445000.0 in Q1 2021.
  • Median Depreciation & Amortization (CF) over the past 5 years was $1.6 million (2023), compared with a mean of $3.0 million.
  • Biggest five-year swings in Depreciation & Amortization (CF): grew 2.87% in 2021 and later skyrocketed 234.27% in 2024.
  • TransMedics' Depreciation & Amortization (CF) stood at $466000.0 in 2021, then skyrocketed by 175.75% to $1.3 million in 2022, then surged by 180.54% to $3.6 million in 2023, then skyrocketed by 57.56% to $5.7 million in 2024, then skyrocketed by 31.48% to $7.5 million in 2025.
  • The last three reported values for Depreciation & Amortization (CF) were $7.5 million (Q4 2025), $6.8 million (Q3 2025), and $6.7 million (Q2 2025) per Business Quant data.